Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.19.1
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended
Mar. 05, 2019
Mar. 31, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]      
Total revenue   $ 43,484 $ 56,157
Royalties      
Disaggregation of Revenue [Line Items]      
Total revenue   19,538 20,820
Promacta      
Disaggregation of Revenue [Line Items]      
Total revenue $ 14,200 14,193 15,573
Kyprolis      
Disaggregation of Revenue [Line Items]      
Total revenue   3,833 3,262
Evomela      
Disaggregation of Revenue [Line Items]      
Total revenue   911 1,600
Other      
Disaggregation of Revenue [Line Items]      
Total revenue   601 385
Material Sales: Captisol      
Disaggregation of Revenue [Line Items]      
Total revenue   8,959 4,391
License fees, milestones and other      
Disaggregation of Revenue [Line Items]      
Total revenue   14,987 30,946
License Fees      
Disaggregation of Revenue [Line Items]      
Total revenue   850 26,955
Milestone      
Disaggregation of Revenue [Line Items]      
Total revenue   11,932 2,825
Other      
Disaggregation of Revenue [Line Items]      
Total revenue   $ 2,205 $ 1,166